Can we cure type 1 diabetes?
DOI:
https://doi.org/10.47196/diab.v56i3Sup.548Keywords:
diabetes mellitus, insulinAbstract
Last year we celebrated the centenary of the discovery of insulin, which occurred at the University of Toronto, Canada, thanks to the research work of Frederick Banting and Charles Best, with the collaboration of James Collip and John Macleod.
Such was the impact that in 1923, Banting and Mcleod were awarded the Nobel Prize for Medicine. Since then, exogenous insulin has been the main hormone replacement therapy in insulin-dependent or insulin-requiring patients. Although this treatment works successfully in most patients, there is a group that does not achieve adequate metabolic goals and is exposed to episodes of hyperglycemia or hypoglycemia, which in the long term determine the appearance of secondary complications of diabetes or cause decompensation and death.
References
I. Bliss M. The discovery of insulin. Toronto: McClelland and Stewart; 1982.
II. Gruessner AC, Gruessner RWG. Pancreas transplantation of US and non-US cases from 2005 to 2014 as Reported to the United Network for Organ Sharing (UNOS) and the International Pancreas Transplant Registry (IPTR). Rev Diabet Stud 2016;13:35-58.
III. Sollinger HW, Odorico JS, Becker YT, D’Alessandroj AM, Pirsch JD. One thousand simultaneous pancreas-kidney transplants at a single center with 22-year follow-Up. Ann Surg. 2009;250:618-630.
IV. The CITR Coordinating Center and Investigators. 9th Collaborative Islet Transplant Registry 2014 Annual Report.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 on behalf of the authors. Reproduction rights: Argentine Diabetes Society
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Dirección Nacional de Derecho de Autor, Exp. N° 5.333.129. Instituto Nacional de la Propiedad Industrial, Marca «Revista de la Sociedad Argentina de Diabetes - Asociación Civil» N° de concesión 2.605.405 y N° de disposición 1.404/13.
La Revista de la SAD está licenciada bajo Licencia Creative Commons Atribución – No Comercial – Sin Obra Derivada 4.0 Internacional.
Por otra parte, la Revista SAD permite que los autores mantengan los derechos de autor sin restricciones.
